ArticleJournal of gastroenterology and hepatology2012
Interleukin-37 reduces liver inflammatory injury via effects on hepatocytes and non-parenchymal cells.
Article in Journal of gastroenterology and hepatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 131 citations in OpenAlex.
- IL-37/IL-1R8 axis: a novel major mechanism of control at the interface between tumor and immune cells.Oncoimmunology · 2026Review
- Research progress on the role of IL‑37 in gynecological and obstetrics‑related diseases (Review).International journal of molecular medicine · 2026Review
- Interleukin-37 Serum Levels in Oral Squamous Cell Carcinoma.Journal of dentistry (Shiraz, Iran) · 2026Article
- Protective effect of ischemic preconditioning against hepatic ischemia-reperfusion injury and associated remote organ damage.World journal of gastrointestinal surgery · 2026Review
- IL-37 ameliorates acetaminophen-induced acute liver injury by limiting MAPK/NFκB signaling-mediated liver inflammation.Scientific reports · 2025Article
- The role of IL-36 and 37 in hepatocellular carcinoma.Frontiers in immunology · 2024Review
- Research Progress on the Role and Mechanism of IL-37 in Liver Diseases.Seminars in liver disease · 2023Article
- Polymorphism Analysis of Interleukin-18 and Interleukin-37 Genes in Hepatitis B Infections with Different Outcomes: A Preliminary Report from an Iranian Population.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Exogenous Interleukin-37 Alleviates Hepatitis with Reduced Dendritic Cells and Induced Regulatory T Cells in Acute Murine Cytomegalovirus Infection.Journal of immunology research · 2023Article
- Serum levels of IL-37 and correlation with inflammatory cytokines and clinical outcomes in patients with coronary artery disease.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2022Article
- IL-37 alleviates liver granuloma caused by Schistosoma japonicum infection by inducing alternative macrophage activation.Parasites & vectors · 2022Article
- Recent Advances in Progresses and Prospects of IL-37 in Central Nervous System Diseases.Brain sciences · 2022Review
- Moscatilin suppresses the inflammation from macrophages and T cells.Open medicine (Warsaw, Poland) · 2022Article
- Protective Effects of Interleukin-37 Expression against Acetaminophen-Induced Hepatotoxicity in Mice.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- IL-33, IL-37, and Vitamin D Interaction Mediate Immunomodulation of Inflammation in Degenerating Cartilage.Antibodies (Basel, Switzerland) · 2021Article
- The Ameliorative Effects of Saikosaponin in Thioacetamide-Induced Liver Injury and Non-Alcoholic Fatty Liver Disease in Mice.International journal of molecular sciences · 2021Article
- IL-37b alleviates endothelial cell apoptosis and inflammation in Kawasaki disease through IL-1R8 pathway.Cell death & disease · 2021Article
- Association of theDiagnostics (Basel, Switzerland) · 2021Article
- The Ameliorative Effects of Fucoidan in Thioacetaide-Induced Liver Injury in Mice.Molecules (Basel, Switzerland) · 2021Article
- Role of IL-37- and IL-37-Treated Dendritic Cells in Acute Coronary Syndrome.Oxidative medicine and cellular longevity · 2021Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
BACKGROUND AND
aimThe purpose of the present study was to determine the effects of interleukin-37 (IL-37) on liver cells and on liver inflammation induced by hepatic ischemia/reperfusion (I/R).
methodsMice were subjected to I/R. Some mice received recombinant IL-37 (IL-37) at the time of reperfusion. Serum levels of alanine aminotransferase, and liver myeloperoxidase content were assessed. Serum and liver tumor necrosis factor-α (TNF-α), macrophage inflammatory protein-2 (MIP-2) and keratinocyte chemokine (KC) were also assessed. Hepatic reactive oxygen species (ROS) levels were assessed. For in vitro experiments, isolated hepatocytes and Kupffer cells were treated with IL-37 and inflammatory stimulants. Cytokine and chemokine production by these cells were assessed. Primary hepatocytes underwent induced cell injury and were treated with IL-37 concurrently. Hepatocyte cytotoxicity and Bcl-2 expression were determined. Isolated neutrophils were treated with TNF-α and IL-37 and neutrophil activation and respiratory burst were assessed.
resultsIL-37 reduced hepatocyte injury and neutrophil accumulation in the liver after I/R. These effects were accompanied by reduced serum levels of TNF-α and MIP-2 and hepatic ROS levels. IL-37 significantly reduced MIP-2 and KC productions from lipopolysaccharide-stimulated hepatocytes and Kupffer cells. IL-37 significantly reduced cell death and increased Bcl-2 expression in hepatocytes. IL-37 significantly suppressed TNF-α-induced neutrophil activation.
conclusionsIL-37 is protective against hepatic I/R injury. These effects are related to the ability of IL-37 to reduce proinflammatory cytokine and chemokine production by hepatocytes and Kupffer cells as well as having a direct protective effect on hepatocytes. In addition, IL-37 contributes to reduce liver injury through suppression of neutrophil activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.